The Latest Breaking News from OGN

Value stocks tend to perform well during economic recoveries and periods of market volatility, making them a good option for long-term investors seeking stability and growth. Additionally, these stocks often pay dividends, offering an additional income stream. Hence, fundamentally solid value stocks Enterprise Products (EPD), Energy Transfer (ET), and Organon…

The pharmaceutical sector is experiencing rapid growth thanks to the rising demand for precision drugs, the growing geriatric population, and an uptick in chronic diseases. Given this backdrop, long-term value investors could consider buying and holding quality pharmaceutical stocks such as Organon (OGN), Procaps (PROC), Johnson & Johnson (JNJ), and…

The pharmaceutical sector is expected to grow rapidly in the coming years, owing to rising worldwide medical needs. Given the industry’s solid prospects, investors could consider buying quality pharma stocks such as Eagle Pharmaceuticals (EGRX), Organon (OGN), and Collegium Pharmaceutical (COLL) this month. Read on.

YouNeek Studios returns to Dark Horse for The Asiri Vol. 1, a new sci-fi/fantasy superhero story

Alydia Health's Jada system for postpartum hemorrhage took 11 years to reach the market; being a women's health product made its road tougher.

'Several diversity, equity, and inclusion demographic factors already impact the global economy,' Bank of America analysts say.

Despite bearish market sentiment, the healthcare industry has outperformed the broader market thanks to its defensive nature. Given overwhelming demand and the need for global healthcare development, we think the stocks of quality healthcare companies Cigna (CI), Organon (OGN), and Bristol-Myers Squibb (BMY) could be solid bets now. These stocks…

Organon easily beat first-quarter expectations Thursday despite a dive for its flagship product, Nexplanon, and OGN stock popped.

Organon offered a light 2022 sales outlook on Thursday, but OGN stock recovered from an early dip following the company's beat.